The Role of MIF in Type 1 and Type 2 Diabetes Mellitus

Sánchez-Zamora, Yuriko Itzel; Rodrı́guez-Sosa, Miriam

doi:10.1155/2014/804519

Cited by 61 publications

(48 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This effect may be explained by the fact that MIF inhibits mitogen-activated protein kinase (MAPK) phosphatase-1, which is induced by glucocorticoids (7). In addition, MIF has been implicated in several types of inflammatory diseases, including atherosclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, psoriasis and diabetes (8,9). Therefore, at present, studies are focusing on the identification and development of pharmacological agents capable of interfering with MIF activity.…”

Section: Introductionmentioning

confidence: 99%

Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets

et al. 2016

View full text Add to dashboard Cite

Abstract. Macrophage migration inhibitory factor (MIF) was originally identified in 1966 by Bloom and Bennett as a pro-inflammatory cytokine involved in the inhibition of macrophage motility. Since then, studies have investigated the functional contribution of this pro-inflammatory cytokine in several immune diseases, including rheumatoid arthritis and lupus erythematous. Recently, MIF has been reported to be involved in a variety of neoplastic diseases. The present review discusses previous cancer research studies that have investigated the involvement of MIF in carcinogenesis, disease prognosis, tumor cell proliferation and invasion, and tumor-induced angiogenesis. Finally, potential therapeutic approaches based on the use of MIF antagonists and neutralizing antibodies are examined. The review concludes that MIF could be a good prognostic biomarker in several types of cancer, but also that the inhibition of MIF could represent a novel therapy against cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets

et al. 2016

View full text Add to dashboard Cite

show abstract

“…MIF has been shown to be involved in a wide range of diseases such as cancer (11,24), atherosclerosis (46), diabetes (34), and several inflammatory conditions (4,19). In the lungs, MIF can be found in macrophages, lymphocytes, eosinophils, and the capillary endothelium (4,8,22,31,45).…”

mentioning

confidence: 99%

Macrophage migration inhibitory factor, a role in COPD

Husebø

Bakke

Grønseth

et al. 2016

American Journal of Physiology-Lung Cellular and Molecular Phys

View full text Add to dashboard Cite

Macrophage migration inhibitor factor (MIF) is a pluripotent cytokine associated with several different inflammatory conditions, but its role within lung inflammation and chronic obstructive pulmonary disease (COPD) is unclear. This study aimed to examine MIF in both stable COPD and during acute exacerbations (AECOPD). The study included 433 patients with COPD aged 41–76 and 325 individuals from the Bergen COPD cohort study who served as controls. All patients had an FEV1 of <80% predicted, FEV1/FVC ratio of <0.7, and a smoking history >10 pack-years. Serum levels of MIF were compared between the two groups at baseline, and for 149 patients, measurements were also carried out during AECOPD. Linear regression models were fitted with MIF as the outcome variable and adjusted for sex, age, body composition, smoking, and Charlson Comorbidity Score (CCS). Median MIF (interquartile range) in patients with COPD was 20.1 ng/ml (13.5–30.9) compared with 14.9 ng/ml (11.1–21.6) in controls ( P < 0.01). MIF was bivariately associated with sex, body composition, and CCS ( P < 0.05 for all). In the regression analyses, MIF was significantly higher in patients with COPD, coefficient 1.32 ( P < 0.01) and 1.30 ( P < 0.01) unadjusted and adjusted, respectively. In addition, in 149 patients during episodes of AECOPD, MIF was significantly elevated, with a median of 23.2 ng/ml (14.1–42.3) compared with measurements at stable disease of 19.3 ng/ml (12.4–31.3, P < 0.01). Serum levels of MIF were significantly higher in patients with COPD compared with controls. We also identified an additional increase in MIF levels during episodes of AECOPD.

show abstract

“…O Diabetes Mellitus (DM) é caracterizado por elevados níveis de glicose no sangue decorrente de falha na produção e/ou incapacidade da insulina em desempenhar adequadamente as suas funções (1) . Sua complexidade associada à elevada incidência e prevalência concorrem para que essa doença seja considerada um importante problema de saúde pública (2) .…”

Section: Introductionunclassified

“…Sua ocorrência está associada a comportamentos, como a alimentação não saudável, sedentarismo, fatores de risco como a obesidade e hipertensão, além de fatores genéticos (1) . O descontrole glicêmico ou o diagnóstico tardio aumentam a chance de complicações, tais como doenças cardiovasculares, retinopatia, nefropatia e pé diabético (1) . O pé diabético ocorre quando uma área lesionada ou infeccionada nos pés desenvolve úlcera (5) .…”

Section: Introductionunclassified

See 1 more Smart Citation

Fatores De Risco Para Ulceração No Pé De Indivíduos Com Diabetes Mellitus Tipo 2

Teston

Senteio

Ribeiro³

et al. 2017

Cogitare Enferm.

View full text Add to dashboard Cite

RISK FACTORS FOR FOOT ULCERATION IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUSABSTRACT: The aim of this study was to analyze the factors associated with the risk of foot ulceration in individuals with type 2 diabetes mellitus. Quantitative study, with 71 individuals in a Primary Health Unit of a municipality in the state of Paraná. The data were collected through a home interview and a physical examination of the feet, from July to September 2016. The foot with risk of ulceration was identified in 35.2% of the studied population. The most prevalent risk factors for ulceration were inadequate nail cutting, use of inadequate footwear, presence of mycosis, callosities and cracked or dry skin. Inadequate capillary filling, loss of sensitivity and history of ulcers were associated with the risk of ulceration. Health professionals should recognize and value the importance of the foot examination and the provision of theoretical and practical guidance regarding foot care for individuals with diabetes. DESCRIPTORS: Diabetes mellitus; Nursing; Primary healthcare; Risk factors. FACTORES DE RIESGO PARA ULCERACIÓN EN LOS PIES DE INDIVIDUOS CON DIABETES MELLITUS TIPO 2RESUMEN: Fue objetivo del estudio analizar los factores asociados al riesgo de ulceración de los pies de individuos con diabetes mellitus tipo 2. Estudio cuantitativo, con 71 individuos en una Unidad Básica de Salud de un municipio del estado de Paraná. Los datos fueron obtenidos en entrevista domiciliar y con prueba física de los pies, en el periodo de julio a septiembre de 2016. El pie con riesgo de ulceración fue identificado en 35,2% de la población estudiada. Los factores de riesgo de ulceraciones más prevalentes fueron el corte inadecuado de las uñas, la utilización de zapatos inadecuados, presencia de micosis, callosidades, rajadura y piel seca. El llenado capilar inadecuado, la pérdida de sensibilidad y el histórico de úlceras estuvieron asociados al riesgo de ulceración. Se concluye que es esencial que los profesionales de salud reconozcan y valoren la importancia de la prueba de los pies y de orientaciones teóricas y prácticas acerca de los cuidados necesarios a los pies de individuos con diabetes. DESCRIPTORES: Diabetes mellitus; Enfermería; Atención básica a la salud; Factores de riesgo.

show abstract

The Role of MIF in Type 1 and Type 2 Diabetes Mellitus

Cited by 61 publications

References 62 publications

Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets

Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets

Macrophage migration inhibitory factor, a role in COPD

Fatores De Risco Para Ulceração No Pé De Indivíduos Com Diabetes Mellitus Tipo 2

Contact Info

Product

Resources

About